Berenberg has initiated coverage of BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA), citing their leadership positions in mRNA medicine. The investment firm started BioNTech (BNTX) with a buy rating ...

Berenberg initiated coverage of BioNTech (BNTX) with a Buy rating and $130 price target The firm says mRNA will revolutionize the treatment of ...

Echoing this, BioNTech stock's Schaeffer's put/call open interest ratio (SOIR) of 1.14 sits higher than 98% of annual ...

US stock futures fell Tuesday, weighed by heightened geopolitical tensions after Russian President Vladimir Putin issued a ...

In a report released today, Harry Gillis from Berenberg Bank upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price target of $130.00. The company’s shares closed yesterday at $101.87.

Last Friday, Palantir (PLTR) announced the transfer of its Class A stock to the Nasdaq (QQQ) from the New York Stock Exchange ...

The epicenter of the supply is Vaccine Exposed (PFE, MRNA, BNTX, NVAX), R&D Uncertainty (IQV, TMO), Food Hormones (ZTS, ELAN) ...

This is a news collection page for Canberra. Check this page for latest news headlines covering major stories, events from Canberra and surrounding ACT. Get breaking news faster than any other ...

Shares of several vaccine makers including Pfizer and Astrazeneca were down Friday morning following the nomination of Robert ...

The immediate aftermath of the nomination saw vaccine stock prices drop on account of Kennedy’s well-publicized views on ...

Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect Trump said that ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...